Radioiodine therapy reduces the frequency of circulating tumour cells in patients with differentiated thyroid cancer.
circulating tumour cells
differentiated thyroid cancer
measurement limitations
papillary thyroid cancer
quantification
radioiodine therapy
treatment monitoring
Journal
Clinical endocrinology
ISSN: 1365-2265
Titre abrégé: Clin Endocrinol (Oxf)
Pays: England
ID NLM: 0346653
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
revised:
08
01
2021
received:
02
06
2020
accepted:
10
01
2021
pubmed:
24
1
2021
medline:
30
9
2021
entrez:
23
1
2021
Statut:
ppublish
Résumé
The aim of the study was the quantification of circulating tumour cells (CTCs) in differentiated thyroid cancer (DTC) patients before and 6 weeks after radioiodine therapy (RIT). Circulating tumour cells (CTCs) were described more recently in cancer patients, mostly correlating with poor outcome and advanced metastases. Peripheral blood for identification and quantification of CTC before RIT or/and 6 weeks after RIT was provided by 55 DTC patients that received RIT for remnant tissue ablation. 13 follicular thyroid cancer (FTC) patients, 31 papillary thyroid cancer (PTC) patients and 11 patients having the follicular variant PTC (FV-PTC) were included. Peripheral blood mononuclear cells (PBMCs) were isolated and EpCAM-positive CTCs were counted by immune fluorescent staining. A CTC positivity of 31.8% before RIT could be observed. Six weeks after RIT, the CTC positivity was reduced to 13.6%. Paired data at both time points of blood sampling could be gathered for n = 33 DTC patients. These patients had significantly higher CTC numbers before RIT than 6 weeks afterwards (0.27 ± 0.47 vs 0.05 ± 0.15, P = .0215). Additionally, significantly reduced CTC numbers were also demonstrated in pre-RIT CTC-positive patients (0.88 ± 0.43 vs 0.05 ± 0.16, P = .0039). Our results indicate a reducing effect on the number of CTCs by RIT. Therefore, CTC enumeration should be considered as efficient tool for treatment monitoring during RIT.
Substances chimiques
Iodine Radioisotopes
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1004-1011Subventions
Organisme : Duesseldorf School of Oncology (funded by the Comprehensive Cancer Center Duesseldorf/Deutsche Krebshilfe and the Medical Faculty HHU Duesseldorf)
Informations de copyright
© 2021 The Authors. Clinical Endocrinology published by John Wiley & Sons Ltd.
Références
Sherma SI. Thyroid carcinoma. Lancet. 2003;361:501-511.
Verburg FA, Mader U, Tanase K, et al. Life expectancy is reduced in differentiated thyroid cancer patients >/= 45 years old with extensive local tumour invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patients. J Clin Endocrinol Metab. 2013;98:172-180.
Eichhorn W, Tabler H, Lippold R, Lochmann M, Schreckenberger M, Bartenstein P. Prognostic factors determining long-term survival in well-differentiated thyroid cancer: an analysis of four hundred eighty-four patients undergoing therapy and aftercare at the same institution. Thyroid. 2003;13:949-958.
Lamartina L, Grani G, Durante C, Filetti S. Recent advances in managing differentiated thyroid cancer. F1000Res. 2018;7:86.
Ruel E, Thomas S, Dinan M, Perkins JM, Roman SA, Sosa JA. Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer. J Clin Endocrinol Metab. 2015;100:1529-1536.
Lima N, Cavaliere H, Tomimori E, Knobel M, Medeiros-Neto G. Prognostic value of serial serum thyroglobulin determinations after total thyroidectomy for differentiated thyroid cancer. J Endocrinol Invest. 2002;25:110-115.
Crocetti U, Durante C, Attard M, et al. Predictive value of recombinant human TSH stimulation and neck ultrasonography in differentiated thyroid cancer patients. Thyroid. 2008;18:1049-1053.
Spencer CA. Clinical review: Clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC). J Clin Endocrinol Metab. 2011;96:3615-3627.
Badulescu IC, Barbus E, Piciu D. Circulating tumour cells in thyroid carcinoma - the prognostic role of this biomarker. Review of the literature. Clujul Med. 2017;90:256-261.
Fehm TN, Meier-Stiegen F, Driemel C, et al. Diagnostic leukapheresis for CTC analysis in breast cancer patients: CTC frequency, clinical experiences and recommendations for standardized reporting. Cytometry A. 2018;93:1213-1219.
Hall CS, Ross M, Bowman Bauldry JB, et al. Circulating tumour cells in stage IV melanoma patients. J Am Coll Surg. 2018;227:116-124.
Qiu ZL, Wei WJ, Sun ZK, et al. Circulating Tumour cells correlate with Clinicopathological features and outcomes in differentiated thyroid cancer. Cell Physiol Biochem. 2018;48:718-730.
Garcia SA, Weitz J, Scholch S. Circulating tumour cells. Methods Mol Biol. 2018;1692:213-219.
Giuliano M, Shaikh A, Lo HC, et al. Perspective on circulating tumour cell clusters: why it takes a village to metastasize. Cancer Res. 2018;78:845-852.
Manjunath Y, Upparahalli SV, Suvilesh KN, et al. Circulating tumour cell clusters are a potential biomarker for detection of non-small cell lung cancer. Lung Cancer. 2019;134:147-150.
Zeng L, Deng X, Zhong J, et al. Prognostic value of biomarkers EpCAM and alphaB-crystallin associated with lymphatic metastasis in breast cancer by iTRAQ analysis. BMC Cancer. 2019;19:831.
Ensinger C, Kremser R, Prommegger R, Spizzo G, Schmid KW. EpCAM overexpression in thyroid carcinomas: a histopathological study of 121 cases. J Immunother. 2006;29:569-573.
Xu JY, Handy B, Michaelis CL, et al. Detection and prognostic significance of circulating tumour cells in patients with metastatic thyroid cancer. J Clin Endocrinol Metab. 2016;101:4461-4467.
Ehlers M, Allelein S, Schwarz F, et al. Increased numbers of circulating tumour cells in thyroid cancer patients. Horm Metab Res. 2018;50:602-608.
Nel I, Jehn U, Gauler T, Hoffmann AC. Individual profiling of circulating tumour cell composition in patients with non-small cell lung cancer receiving platinum based treatment. Transl Lung Cancer Res. 2014;3:100-106.
Ehlers M, Allelein S, Haase M, Willenberg HS, Knoefel WT, Schott M. Circulating tumour cells in patients with neuroendocrine neoplasms. Horm Metab Res. 2014;46:744-745.
Li J, Fu W, Zhang W, Li P. High number of circulating tumour cells predicts poor survival of cutaneous melanoma patients in china. Med Sci Monit. 2018;24:324-331.
Schmidt M, Gorges R, Drzezga A, Dietlein M. A matter of controversy: is radioiodine therapy favorable in differentiated thyroid carcinoma? J Nucl Med. 2018;59:1195-1201.
Brendel AJ, Lambert B, Guyot M, et al. Low levels of serum thyroglobulin after withdrawal of thyroid suppression therapy in the follow up of differentiated thyroid carcinoma. Eur J Nucl Med. 1990;16:35-38.
Cherk MH, Francis P, Topliss DJ, Bailey M, Kalff V. Incidence and implications of negative serum thyroglobulin but positive I-131 whole-body scans in patients with well-differentiated thyroid cancer prepared with rhTSH or thyroid hormone withdrawal. Clin Endocrinol (Oxf). 2012;76:734-740.
Alvarez-Cubero MJ, Vazquez-Alonso F, Puche-Sanz I, et al. Dormant circulating tumour cells in prostate cancer: therapeutic, clinical and biological implications. Curr Drug Targets. 2016;17:693-701.
de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumour cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14:6302-6309.
Chen HHW, Kuo MT. Improving radiotherapy in cancer treatment: promises and challenges. Oncotarget. 2017;8:62742-62758.
Perumal V, Corica T, Dharmarajan AM, et al. Circulating Tumour Cells (CTC), head and neck cancer and radiotherapy; future perspectives. Cancers (Basel). 2019;11:367.
Tagawa ST, Vallabhajosula S, Christos PJ, et al. Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 ((177) Lu-J591) for metastatic castration-resistant prostate cancer. Cancer. 2019;125:2561-2569.
Budna-Tukan J, Swierczewska M, Mazel M, et al. Analysis of circulating tumour cells in patients with non-metastatic high-risk prostate cancer before and after radiotherapy using three different enumeration assays. Cancers (Basel). 2019;11.802;https://doi.org/10.3390/cancers11060802
Goodman CR, Seagle BL, Friedl TWP, et al. Association of circulating tumour cell status with benefit of radiotherapy and survival in early-stage breast cancer. JAMA Oncol. 2018;4:e180163.
Dorsey JF, Kao GD, MacArthur KM, et al. Tracking viable circulating tumour cells (CTCs) in the peripheral blood of non-small cell lung cancer (NSCLC) patients undergoing definitive radiation therapy: pilot study results. Cancer. 2015;121:139-149.
Heller G, McCormack R, Kheoh T, et al. Circulating tumour cell number as a response measure of prolonged survival for metastatic castration-resistant prostate cancer: a comparison with prostate-specific antigen across five randomized phase III clinical trials. J Clin Oncol. 2018;36:572-580.
Lorente D, Olmos D, Mateo J, et al. Decline in circulating tumour cell count and treatment outcome in advanced prostate cancer. Eur Urol. 2016;70:985-992.